2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 370

Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)
Abstract Number: 1300

Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Abstract Number: 1622

Characteristics of Patients with Infectious Cryoglobulinemia Vasculitis in the Absence of HCV Infection: Results From the French Nationwide Cryovas Survey
Abstract Number: 2374

Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behcet’s Syndrome: Experience in A Dedicated Center
Abstract Number: 505

Characterization of an in Vitro Model of Human Salivary Gland for Studying Sjögren Syndrome (SS)
Abstract Number: 2577

Characterization of Circulating Human B Cells That Bind Cyclic Citrullinated Peptide Antigens in Clinically Active Rheumatoid Arthritis
Abstract Number: 1401

Characterization of Clinical Photosensitivity in Cutaneous Lupus Erythematosus
Abstract Number: 516

Characterization of Dominant B- and Plasma Cell Clones in Patients with Primary Sjögren’s Syndrome and Patients with Sicca Syndrome
Abstract Number: 1671

Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Abstract Number: 204

Characterization of Joint Disease in Mucopolysaccharidosis Type I Mice and the Effects of Enzyme Replacement Therapy
Abstract Number: 1113

Characterization of Lumbar Spine Individual Radiographic Features in African American and White Women and Men: The Johnston County Osteoarthritis Project
Abstract Number: 691

Characterization of Pro-Inflammatory Cytokines and Vitamin D Levels in a Lupus Cohort and Correlation with Disease Activity
Abstract Number: 2239

Characterization of Pure Membranous Lupus Nephritis: A Cohort of 150 Patients
Abstract Number: 1454

Characterization of Renal Mononuclear Phagocyte Populations in Murine SLE Nephritis
Abstract Number: 734

Chemokine (C-C Motif) Receptor 2 Signaling Mediates Persistent Pain in Experimental Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].